FDA expands approval of flu treatment to post-exposure prevention
The Food and Drug Administration yesterday approved using the antiviral treatment Xofluza (baloxavir marboxil) to prevent flu in patients age 12 or older who have been exposed to someone with flu.
“This expanded indication for Xofluza will provide an important option to help prevent influenza just in time for a flu season that is anticipated to be unlike any other because it will coincide with the coronavirus pandemic,” said Debra Birnkrant, M.D., director of the FDA’s Division of Antiviral Products.
Related News Articles
Headline
The Administration for Strategic Preparedness and Response June 25 announced a flu pandemic preparedness and response strategy in response to the threat of…
Headline
The Food and Drug Administration last week granted enforcement discretion for the use of conjunctival swabs by laboratories as part of human testing for H5N1…
Headline
The Centers for Disease Control and Prevention May 21 announced recommendations that flu surveillance systems continue operating at enhanced levels during the…
Headline
The Food and Drug Administration recently granted emergency use authorization for the first over-the-counter home antigen test to detect both flu and COVID-19…
Headline
The Home Test to Treat program now offers free testing, telehealth and treatment for both COVID-19 and flu to eligible adults nationwide, the National…
Headline
Flu-associated medical visits and hospitalizations per 100,000 population in 2022-23 were higher among children under age 5 than for older children, but were…